| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Flavonoids | 22 | 2012 | 77 | 5.160 |
Why?
|
| Glucuronides | 21 | 2012 | 24 | 4.980 |
Why?
|
| Glucuronosyltransferase | 17 | 2012 | 68 | 4.790 |
Why?
|
| Genistein | 17 | 2012 | 39 | 3.510 |
Why?
|
| Intestinal Mucosa | 22 | 2012 | 784 | 2.930 |
Why?
|
| Intestinal Absorption | 21 | 2012 | 190 | 2.810 |
Why?
|
| Isoflavones | 13 | 2009 | 43 | 2.480 |
Why?
|
| Caco-2 Cells | 28 | 2012 | 94 | 2.360 |
Why?
|
| Phenols | 7 | 2012 | 53 | 2.300 |
Why?
|
| Microsomes | 10 | 2010 | 55 | 1.800 |
Why?
|
| Microsomes, Liver | 12 | 2012 | 91 | 1.730 |
Why?
|
| Tandem Mass Spectrometry | 14 | 2012 | 248 | 1.670 |
Why?
|
| ATP-Binding Cassette Transporters | 7 | 2012 | 190 | 1.580 |
Why?
|
| Biological Availability | 22 | 2012 | 147 | 1.560 |
Why?
|
| Chromatography, High Pressure Liquid | 15 | 2011 | 345 | 1.260 |
Why?
|
| Biological Transport | 25 | 2012 | 353 | 1.220 |
Why?
|
| Sulfotransferases | 4 | 2012 | 27 | 1.190 |
Why?
|
| Flavones | 5 | 2012 | 10 | 1.180 |
Why?
|
| Flavonols | 4 | 2011 | 9 | 1.150 |
Why?
|
| Intestines | 12 | 2012 | 580 | 1.140 |
Why?
|
| Chromatography, Liquid | 10 | 2012 | 210 | 1.080 |
Why?
|
| Rats | 32 | 2012 | 3764 | 1.020 |
Why?
|
| Liver | 9 | 2012 | 1758 | 0.990 |
Why?
|
| Models, Molecular | 4 | 2012 | 1094 | 0.950 |
Why?
|
| Plant Extracts | 4 | 2012 | 126 | 0.920 |
Why?
|
| Neoplasm Proteins | 4 | 2012 | 687 | 0.900 |
Why?
|
| Flavanones | 4 | 2012 | 6 | 0.870 |
Why?
|
| Apigenin | 8 | 2012 | 9 | 0.850 |
Why?
|
| Isoenzymes | 4 | 2011 | 233 | 0.830 |
Why?
|
| Raloxifene Hydrochloride | 3 | 2010 | 16 | 0.810 |
Why?
|
| Kinetics | 16 | 2012 | 1330 | 0.790 |
Why?
|
| Ginsenosides | 2 | 2012 | 19 | 0.750 |
Why?
|
| Rats, Sprague-Dawley | 18 | 2012 | 1261 | 0.730 |
Why?
|
| Molecular Structure | 9 | 2012 | 296 | 0.710 |
Why?
|
| Protein Isoforms | 7 | 2011 | 405 | 0.710 |
Why?
|
| Cytochrome P-450 Enzyme System | 4 | 2012 | 135 | 0.670 |
Why?
|
| Administration, Oral | 10 | 2012 | 703 | 0.670 |
Why?
|
| Anticarcinogenic Agents | 3 | 2012 | 57 | 0.670 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2010 | 46 | 0.660 |
Why?
|
| Animals | 51 | 2012 | 34548 | 0.650 |
Why?
|
| Recombinant Proteins | 8 | 2012 | 1402 | 0.630 |
Why?
|
| Intestine, Small | 3 | 2008 | 311 | 0.620 |
Why?
|
| Models, Biological | 9 | 2012 | 1471 | 0.570 |
Why?
|
| Pharmaceutical Preparations | 3 | 2012 | 80 | 0.560 |
Why?
|
| Mixed Function Oxygenases | 4 | 2003 | 30 | 0.550 |
Why?
|
| Polymyxin B | 3 | 2012 | 47 | 0.530 |
Why?
|
| Dipeptidases | 5 | 2003 | 14 | 0.520 |
Why?
|
| Substrate Specificity | 7 | 2012 | 296 | 0.480 |
Why?
|
| Perfusion | 9 | 2012 | 206 | 0.470 |
Why?
|
| Estrone | 2 | 2004 | 9 | 0.460 |
Why?
|
| Antineoplastic Agents | 5 | 2011 | 1730 | 0.450 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2011 | 19 | 0.450 |
Why?
|
| Dietary Supplements | 2 | 2010 | 474 | 0.440 |
Why?
|
| Humans | 64 | 2012 | 126366 | 0.420 |
Why?
|
| Panax | 1 | 2012 | 7 | 0.390 |
Why?
|
| Estrous Cycle | 1 | 2012 | 35 | 0.390 |
Why?
|
| Lactase-Phlorizin Hydrolase | 2 | 2012 | 21 | 0.390 |
Why?
|
| Pterocarpans | 2 | 2011 | 2 | 0.380 |
Why?
|
| Sulfur Compounds | 1 | 2011 | 4 | 0.380 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 155 | 0.370 |
Why?
|
| Alkaloids | 3 | 2011 | 34 | 0.370 |
Why?
|
| Cephalosporins | 4 | 1996 | 139 | 0.370 |
Why?
|
| Multidrug Resistance-Associated Proteins | 5 | 2011 | 22 | 0.360 |
Why?
|
| Quinolizines | 2 | 2011 | 7 | 0.360 |
Why?
|
| Trifolium | 2 | 2008 | 2 | 0.350 |
Why?
|
| Hot Temperature | 2 | 2008 | 140 | 0.350 |
Why?
|
| Hypericum | 1 | 2010 | 1 | 0.350 |
Why?
|
| Quinazolines | 2 | 2004 | 175 | 0.340 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2010 | 41 | 0.340 |
Why?
|
| Drug Interactions | 6 | 2010 | 254 | 0.330 |
Why?
|
| Estrogens | 1 | 2012 | 505 | 0.330 |
Why?
|
| Tissue Distribution | 6 | 2012 | 394 | 0.330 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 677 | 0.320 |
Why?
|
| Phytoestrogens | 2 | 2007 | 15 | 0.320 |
Why?
|
| Biotransformation | 5 | 2012 | 50 | 0.310 |
Why?
|
| Hydrolysis | 6 | 2012 | 161 | 0.310 |
Why?
|
| Coumarins | 1 | 2008 | 22 | 0.310 |
Why?
|
| Injections, Intravenous | 5 | 2012 | 248 | 0.310 |
Why?
|
| Anti-Bacterial Agents | 6 | 2012 | 2406 | 0.300 |
Why?
|
| Epimedium | 1 | 2008 | 1 | 0.300 |
Why?
|
| Nucleosides | 3 | 2004 | 17 | 0.290 |
Why?
|
| Quantitative Structure-Activity Relationship | 3 | 2012 | 15 | 0.280 |
Why?
|
| Morphinans | 1 | 2006 | 2 | 0.270 |
Why?
|
| Male | 31 | 2012 | 62042 | 0.270 |
Why?
|
| Bridged-Ring Compounds | 1 | 2006 | 17 | 0.270 |
Why?
|
| Rats, Wistar | 5 | 2011 | 382 | 0.270 |
Why?
|
| Benzoates | 1 | 2006 | 21 | 0.260 |
Why?
|
| Glucosides | 1 | 2006 | 47 | 0.260 |
Why?
|
| Bile | 3 | 2012 | 46 | 0.260 |
Why?
|
| Cephalexin | 2 | 1996 | 7 | 0.250 |
Why?
|
| Mice | 14 | 2012 | 17877 | 0.250 |
Why?
|
| Up-Regulation | 1 | 2009 | 876 | 0.250 |
Why?
|
| Hydrogen-Ion Concentration | 8 | 2004 | 454 | 0.250 |
Why?
|
| Permeability | 3 | 2012 | 125 | 0.250 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2005 | 10 | 0.250 |
Why?
|
| Dipeptides | 4 | 1995 | 59 | 0.240 |
Why?
|
| Biological Products | 1 | 2007 | 128 | 0.240 |
Why?
|
| Food Labeling | 1 | 2004 | 10 | 0.230 |
Why?
|
| Soybean Proteins | 1 | 2004 | 17 | 0.230 |
Why?
|
| Binding Sites | 3 | 2012 | 1314 | 0.230 |
Why?
|
| Polyphenols | 3 | 2010 | 20 | 0.230 |
Why?
|
| Area Under Curve | 4 | 2012 | 324 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 308 | 0.220 |
Why?
|
| Enzyme Inhibitors | 3 | 2009 | 592 | 0.220 |
Why?
|
| Species Specificity | 4 | 2011 | 553 | 0.220 |
Why?
|
| Methionine | 2 | 1994 | 103 | 0.220 |
Why?
|
| Absorption | 3 | 2012 | 52 | 0.220 |
Why?
|
| Ginkgo biloba | 1 | 2003 | 12 | 0.210 |
Why?
|
| Colon | 2 | 2005 | 358 | 0.210 |
Why?
|
| Biomarkers | 2 | 2011 | 3154 | 0.210 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2003 | 47 | 0.210 |
Why?
|
| Carrier Proteins | 3 | 2005 | 1031 | 0.200 |
Why?
|
| Injections, Intraperitoneal | 2 | 2012 | 75 | 0.200 |
Why?
|
| Mice, Knockout | 5 | 2012 | 3775 | 0.200 |
Why?
|
| Sulfates | 2 | 2012 | 35 | 0.200 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2007 | 188 | 0.200 |
Why?
|
| Metabolic Detoxication, Phase II | 2 | 2012 | 14 | 0.190 |
Why?
|
| Propionates | 3 | 2009 | 31 | 0.190 |
Why?
|
| Metabolic Clearance Rate | 3 | 2012 | 144 | 0.190 |
Why?
|
| DNA, Complementary | 3 | 2003 | 465 | 0.180 |
Why?
|
| Catalytic Domain | 2 | 2012 | 163 | 0.180 |
Why?
|
| Quinolines | 3 | 2009 | 106 | 0.180 |
Why?
|
| Cytochrome P-450 CYP3A | 4 | 2012 | 59 | 0.180 |
Why?
|
| Emodin | 2 | 2010 | 2 | 0.180 |
Why?
|
| Cell Membrane Permeability | 4 | 2004 | 74 | 0.180 |
Why?
|
| HeLa Cells | 2 | 2012 | 799 | 0.170 |
Why?
|
| Amino Acid Sequence | 5 | 2012 | 2728 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2011 | 2901 | 0.170 |
Why?
|
| Gastrointestinal Tract | 2 | 2012 | 214 | 0.160 |
Why?
|
| Temperature | 5 | 2004 | 309 | 0.160 |
Why?
|
| Protein Conformation | 2 | 2012 | 839 | 0.160 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1999 | 106 | 0.160 |
Why?
|
| Peptides | 4 | 1996 | 820 | 0.160 |
Why?
|
| Oxidoreductases | 1 | 1999 | 93 | 0.160 |
Why?
|
| Gene Silencing | 2 | 2011 | 243 | 0.150 |
Why?
|
| Leukotriene C4 | 2 | 2011 | 4 | 0.150 |
Why?
|
| In Vitro Techniques | 4 | 2009 | 973 | 0.150 |
Why?
|
| Prodrugs | 3 | 2003 | 58 | 0.150 |
Why?
|
| Reference Standards | 2 | 2010 | 236 | 0.150 |
Why?
|
| Thymidylate Synthase | 1 | 1998 | 22 | 0.150 |
Why?
|
| Dogs | 4 | 2012 | 773 | 0.150 |
Why?
|
| Genetic Vectors | 2 | 1999 | 942 | 0.150 |
Why?
|
| Cyclosporine | 2 | 2011 | 145 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 4 | 2011 | 1072 | 0.140 |
Why?
|
| Midazolam | 2 | 2012 | 45 | 0.140 |
Why?
|
| Lipase | 1 | 1997 | 94 | 0.140 |
Why?
|
| Polymorphism, Genetic | 1 | 2000 | 820 | 0.140 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 1996 | 42 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 2071 | 0.130 |
Why?
|
| Phenylalanine | 3 | 2000 | 128 | 0.130 |
Why?
|
| Tetrahydroisoquinolines | 1 | 1995 | 11 | 0.120 |
Why?
|
| Isoquinolines | 1 | 1995 | 41 | 0.120 |
Why?
|
| Epithelium | 5 | 1994 | 363 | 0.120 |
Why?
|
| Carcinogens | 3 | 2011 | 149 | 0.120 |
Why?
|
| Stereoisomerism | 2 | 2011 | 109 | 0.120 |
Why?
|
| Biocatalysis | 2 | 2012 | 34 | 0.120 |
Why?
|
| Isomerism | 2 | 2011 | 30 | 0.120 |
Why?
|
| Osmolar Concentration | 2 | 2011 | 176 | 0.120 |
Why?
|
| Cells, Cultured | 5 | 2011 | 3045 | 0.110 |
Why?
|
| Jejunum | 3 | 2012 | 127 | 0.110 |
Why?
|
| Organic Anion Transporters | 2 | 2004 | 16 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1995 | 219 | 0.110 |
Why?
|
| Enzyme Stability | 2 | 2007 | 58 | 0.110 |
Why?
|
| Zidovudine | 1 | 1993 | 23 | 0.110 |
Why?
|
| Cell Line, Tumor | 3 | 2012 | 3458 | 0.110 |
Why?
|
| Thymidine | 1 | 1993 | 54 | 0.110 |
Why?
|
| Verapamil | 2 | 2011 | 53 | 0.100 |
Why?
|
| Amino Acids | 3 | 1994 | 669 | 0.100 |
Why?
|
| Teichoic Acids | 1 | 2012 | 13 | 0.100 |
Why?
|
| Diketopiperazines | 1 | 2012 | 3 | 0.100 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2012 | 9 | 0.100 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2012 | 28 | 0.100 |
Why?
|
| Phloretin | 1 | 2012 | 2 | 0.100 |
Why?
|
| Anesthetics, Intravenous | 1 | 2012 | 46 | 0.100 |
Why?
|
| Arylsulfotransferase | 1 | 2012 | 6 | 0.100 |
Why?
|
| Kaempferols | 1 | 2012 | 5 | 0.100 |
Why?
|
| Structural Homology, Protein | 1 | 2012 | 27 | 0.100 |
Why?
|
| Sex Characteristics | 2 | 2011 | 316 | 0.100 |
Why?
|
| Aconitine | 1 | 2011 | 9 | 0.100 |
Why?
|
| Uridine Diphosphate Glucuronic Acid | 1 | 2011 | 6 | 0.100 |
Why?
|
| Membrane Transport Modulators | 1 | 2011 | 5 | 0.100 |
Why?
|
| Hydrogen Bonding | 1 | 2012 | 80 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2012 | 181 | 0.090 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 59 | 0.090 |
Why?
|
| Time Factors | 5 | 2012 | 6338 | 0.090 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 3907 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2012 | 800 | 0.090 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2012 | 107 | 0.090 |
Why?
|
| Adenosine | 1 | 2012 | 129 | 0.090 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 241 | 0.090 |
Why?
|
| Diterpenes | 1 | 2011 | 27 | 0.090 |
Why?
|
| Solubility | 1 | 2011 | 142 | 0.090 |
Why?
|
| Molecular Sequence Annotation | 1 | 2012 | 151 | 0.090 |
Why?
|
| Glycosides | 1 | 2011 | 7 | 0.090 |
Why?
|
| Cell Line | 5 | 2012 | 2738 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 102 | 0.090 |
Why?
|
| Cytosol | 1 | 2011 | 163 | 0.090 |
Why?
|
| Catalysis | 1 | 2011 | 129 | 0.090 |
Why?
|
| Mouth Neoplasms | 1 | 2011 | 85 | 0.090 |
Why?
|
| Testosterone | 3 | 2009 | 559 | 0.090 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 363 | 0.090 |
Why?
|
| Calibration | 1 | 2011 | 91 | 0.090 |
Why?
|
| Acinetobacter baumannii | 1 | 2011 | 39 | 0.090 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 302 | 0.090 |
Why?
|
| Cell Division | 3 | 1999 | 765 | 0.090 |
Why?
|
| Klebsiella pneumoniae | 1 | 2011 | 84 | 0.090 |
Why?
|
| Drug Stability | 4 | 1999 | 60 | 0.090 |
Why?
|
| Levodopa | 1 | 1990 | 91 | 0.090 |
Why?
|
| Sequence Alignment | 1 | 2012 | 622 | 0.080 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2010 | 80 | 0.080 |
Why?
|
| Cathartics | 1 | 2010 | 28 | 0.080 |
Why?
|
| Methotrexate | 1 | 2012 | 336 | 0.080 |
Why?
|
| Quality Control | 1 | 2010 | 123 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 771 | 0.080 |
Why?
|
| Dipyridamole | 1 | 2009 | 22 | 0.080 |
Why?
|
| Sodium | 3 | 1998 | 296 | 0.080 |
Why?
|
| Leukotriene Antagonists | 1 | 2009 | 17 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 168 | 0.080 |
Why?
|
| Random Allocation | 1 | 2010 | 443 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 310 | 0.080 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2009 | 52 | 0.080 |
Why?
|
| Butanols | 1 | 2009 | 3 | 0.080 |
Why?
|
| Mannitol | 3 | 2000 | 49 | 0.080 |
Why?
|
| Rats, Gunn | 1 | 2009 | 3 | 0.080 |
Why?
|
| Berberine | 1 | 2009 | 8 | 0.080 |
Why?
|
| Glucuronic Acid | 1 | 2009 | 13 | 0.080 |
Why?
|
| Methyldopa | 1 | 1989 | 4 | 0.080 |
Why?
|
| Captopril | 1 | 1988 | 27 | 0.080 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 362 | 0.080 |
Why?
|
| Azetidines | 1 | 2009 | 57 | 0.080 |
Why?
|
| Indomethacin | 1 | 2009 | 83 | 0.080 |
Why?
|
| Epithelial Cells | 3 | 2004 | 913 | 0.080 |
Why?
|
| Hydroxylation | 2 | 2011 | 48 | 0.080 |
Why?
|
| Female | 10 | 2012 | 67337 | 0.080 |
Why?
|
| Camptothecin | 1 | 2009 | 73 | 0.080 |
Why?
|
| Hesperidin | 1 | 2008 | 2 | 0.080 |
Why?
|
| Glucosidases | 1 | 2008 | 2 | 0.080 |
Why?
|
| Ezetimibe | 1 | 2009 | 94 | 0.080 |
Why?
|
| Prenylation | 1 | 2008 | 2 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 1990 | 390 | 0.070 |
Why?
|
| Fungal Proteins | 1 | 2008 | 133 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2009 | 370 | 0.070 |
Why?
|
| Monoterpenes | 1 | 2006 | 5 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 1692 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2007 | 427 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2009 | 469 | 0.070 |
Why?
|
| Rats, Inbred Strains | 1 | 2006 | 233 | 0.070 |
Why?
|
| Digoxin | 1 | 2006 | 43 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 670 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 235 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2012 | 978 | 0.060 |
Why?
|
| Sex Factors | 1 | 2010 | 1293 | 0.060 |
Why?
|
| Transfection | 2 | 1999 | 1080 | 0.060 |
Why?
|
| Membrane Transport Proteins | 2 | 2004 | 175 | 0.060 |
Why?
|
| Half-Life | 1 | 2005 | 157 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 1113 | 0.060 |
Why?
|
| Kidney | 1 | 2012 | 1361 | 0.060 |
Why?
|
| Plants | 1 | 2005 | 47 | 0.060 |
Why?
|
| Protons | 2 | 1996 | 94 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 649 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 583 | 0.060 |
Why?
|
| Washington | 1 | 2004 | 32 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1558 | 0.060 |
Why?
|
| Biliary Tract | 1 | 2004 | 15 | 0.060 |
Why?
|
| Serum | 1 | 2004 | 46 | 0.050 |
Why?
|
| Oxidoreductases, O-Demethylating | 1 | 2003 | 1 | 0.050 |
Why?
|
| Phenacetin | 1 | 2003 | 3 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2004 | 104 | 0.050 |
Why?
|
| Acetophenones | 1 | 2003 | 13 | 0.050 |
Why?
|
| Binding, Competitive | 2 | 1994 | 193 | 0.050 |
Why?
|
| Models, Animal | 1 | 2005 | 459 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2003 | 51 | 0.050 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2003 | 66 | 0.050 |
Why?
|
| Chromatography, Gel | 1 | 2003 | 95 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2003 | 268 | 0.050 |
Why?
|
| Methylation | 1 | 2003 | 224 | 0.050 |
Why?
|
| Culture Media | 2 | 2012 | 182 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 250 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2003 | 257 | 0.050 |
Why?
|
| Ciprofloxacin | 1 | 2002 | 61 | 0.050 |
Why?
|
| Propranolol | 2 | 2000 | 125 | 0.050 |
Why?
|
| beta-Glucosidase | 1 | 2002 | 2 | 0.050 |
Why?
|
| Apoptosis | 1 | 2009 | 1843 | 0.050 |
Why?
|
| 2,4-Dinitrophenol | 2 | 1992 | 3 | 0.050 |
Why?
|
| Dinitrophenols | 2 | 1992 | 5 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2007 | 526 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 900 | 0.050 |
Why?
|
| Glucuronidase | 2 | 2012 | 31 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2195 | 0.040 |
Why?
|
| Catheterization | 1 | 2002 | 227 | 0.040 |
Why?
|
| Biological Transport, Active | 2 | 2002 | 87 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2000 | 48 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2002 | 261 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 2546 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1562 | 0.040 |
Why?
|
| Sympatholytics | 1 | 1999 | 3 | 0.040 |
Why?
|
| Drug Carriers | 2 | 1992 | 111 | 0.040 |
Why?
|
| Diuretics, Osmotic | 1 | 1999 | 4 | 0.040 |
Why?
|
| Nifedipine | 1 | 1999 | 21 | 0.040 |
Why?
|
| GABA Modulators | 1 | 1999 | 11 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1999 | 67 | 0.040 |
Why?
|
| Tritium | 1 | 1999 | 171 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1999 | 113 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 1999 | 367 | 0.040 |
Why?
|
| Gene Expression | 1 | 2003 | 1563 | 0.040 |
Why?
|
| Base Sequence | 1 | 2003 | 3120 | 0.040 |
Why?
|
| Indoles | 1 | 1999 | 192 | 0.040 |
Why?
|
| Warfarin | 1 | 1999 | 118 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1999 | 258 | 0.040 |
Why?
|
| Mutation | 1 | 2012 | 5961 | 0.040 |
Why?
|
| Purines | 1 | 1998 | 116 | 0.040 |
Why?
|
| Pyridines | 1 | 1999 | 240 | 0.040 |
Why?
|
| Ileum | 1 | 1998 | 134 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1999 | 257 | 0.040 |
Why?
|
| Duodenum | 1 | 1998 | 101 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 554 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 1028 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 1996 | 13 | 0.030 |
Why?
|
| Liposomes | 1 | 1997 | 190 | 0.030 |
Why?
|
| Xenobiotics | 1 | 1996 | 27 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 1208 | 0.030 |
Why?
|
| Diffusion | 1 | 1995 | 58 | 0.030 |
Why?
|
| Neoplasms | 1 | 2010 | 2814 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 1999 | 448 | 0.030 |
Why?
|
| Basement Membrane | 1 | 1995 | 48 | 0.030 |
Why?
|
| Ouabain | 1 | 1994 | 28 | 0.030 |
Why?
|
| Amiloride | 1 | 1994 | 28 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 1031 | 0.030 |
Why?
|
| Anticoagulants | 1 | 1999 | 579 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 1994 | 40 | 0.030 |
Why?
|
| Diffusion Chambers, Culture | 1 | 1994 | 7 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 1994 | 98 | 0.030 |
Why?
|
| Insulin | 1 | 1999 | 1207 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2011 | 2399 | 0.030 |
Why?
|
| Gluconates | 1 | 2012 | 6 | 0.030 |
Why?
|
| Recycling | 1 | 2012 | 5 | 0.030 |
Why?
|
| Glucaric Acid | 1 | 2012 | 10 | 0.030 |
Why?
|
| Uranyl Nitrate | 1 | 2012 | 3 | 0.030 |
Why?
|
| Lactones | 1 | 2012 | 38 | 0.030 |
Why?
|
| Sodium Azide | 1 | 1992 | 4 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 28 | 0.020 |
Why?
|
| Azides | 1 | 1992 | 9 | 0.020 |
Why?
|
| Ions | 1 | 1992 | 22 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 20 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 1992 | 34 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 81 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 131 | 0.020 |
Why?
|
| DNA Topoisomerase IV | 1 | 2012 | 12 | 0.020 |
Why?
|
| DNA Gyrase | 1 | 2012 | 22 | 0.020 |
Why?
|
| Benzoxepins | 1 | 2011 | 1 | 0.020 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2011 | 8 | 0.020 |
Why?
|
| Limonins | 1 | 2011 | 2 | 0.020 |
Why?
|
| Ofloxacin | 1 | 2012 | 32 | 0.020 |
Why?
|
| Glucose | 2 | 2000 | 881 | 0.020 |
Why?
|
| Levofloxacin | 1 | 2012 | 46 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 51 | 0.020 |
Why?
|
| Quinolones | 1 | 2012 | 54 | 0.020 |
Why?
|
| Tyrosine | 1 | 2011 | 154 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2011 | 58 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2011 | 109 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2010 | 63 | 0.020 |
Why?
|
| Creatinine | 1 | 2012 | 395 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2011 | 287 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 414 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 183 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 834 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 510 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2009 | 35 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 1075 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 296 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 40 | 0.020 |
Why?
|
| Excipients | 1 | 1988 | 11 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2009 | 56 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 295 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 796 | 0.020 |
Why?
|
| Basidiomycota | 1 | 2008 | 12 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 626 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 1596 | 0.020 |
Why?
|
| Mathematics | 1 | 1988 | 97 | 0.020 |
Why?
|
| beta-Lactams | 1 | 1988 | 52 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 1646 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 219 | 0.020 |
Why?
|
| Protein Binding | 1 | 1990 | 1762 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 495 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 1463 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 4465 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2002 | 16 | 0.010 |
Why?
|
| Cimetidine | 1 | 2000 | 14 | 0.010 |
Why?
|
| Erythromycin | 1 | 2000 | 20 | 0.010 |
Why?
|
| Atenolol | 1 | 2000 | 43 | 0.010 |
Why?
|
| Mammals | 1 | 2000 | 257 | 0.010 |
Why?
|
| Insulin Lispro | 1 | 1999 | 2 | 0.010 |
Why?
|
| Cresols | 1 | 1999 | 6 | 0.010 |
Why?
|
| Adsorption | 1 | 1999 | 34 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 4640 | 0.010 |
Why?
|